Full Press Release Details
to Present at the 35th Annual J.P. Morgan Healthcare Conference on
Monday, January 9, 2017 at 8:00am PT
NEW YORK--(BUSINESS WIRE)--January 3, 2017--Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS),
a biopharmaceutical company focused on developing immunotherapies based
on gene edited CAR T-cells (UCART), today announced that Dr. Andr
Choulika, Chairman and Chief Executive Officer of Cellectis, will
present at the 35th Annual J.P. Morgan Healthcare Conference
on Monday, January 9, 2017 at 8:00 a.m. Pacific Time in the Elizabethan
A/B room. The conference will be held from January 9 to 12, 2017 at the
Westin St. Francis in San Francisco.
To access the live webcast of Cellectis' presentation and subsequent
breakout session, please visit http://www.cellectis.com/en/events.
A replay of the webcast will be available on Cellectis' website for 90
Cellectis is a biopharmaceutical company focused on developing
immunotherapies based on gene edited CAR T-cells (UCART). The company's
mission is to develop a new generation of cancer therapies based on
engineered T-cells. Cellectis capitalizes on its 17 years of expertise
in genome engineering - based on its flagship TALEN
products and meganucleases and pioneering electroporation PulseAgile
technology - to create a new generation of immunotherapies. CAR
technologies are designed to target surface antigens expressed on cells.
Using its life-science-focused, pioneering genome-engineering
technologies, Cellectis' goal is to create innovative products in
multiple fields and with various target markets. Cellectis is listed on
the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market
(ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com
Talking about gene editing? We do it. TALEN is a
registered trademark owned by the Cellectis Group.
This press release and the information contained herein do not
constitute an offer to sell or subscribe, or a solicitation of an offer
to buy or subscribe, for shares in Cellectis in any country. This press
release contains forward-looking statements that relate to the Company's
objectives based on the current expectations and assumptions of the
Company's management only and involve risk and uncertainties that could
cause the Company to fail to achieve the objectives expressed by the
forward-looking statements above.
For further information, please contact:
Jennifer Moore, 917-580-1088
VP of Communications
Kasunich, 212-896-1241
KCSA Strategic Communications
Simon Harnest, 646-385-9008
VP of Corporate Strategy